Recently, Errafii et al. [117] showed on an in vitro steatosis model (HepG2 cells) that the improvement of steatosis induced by GLP-1 RAs could be explained in part by the activation of the farnesoid X receptor/retinoid X receptor (FXR/RXR) pathway via direct stimulation of the GLP-1R, resulting in the inhibition of de novo lipogenesis. The gene discussed is GCG; the disease is steatosis.